United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Sol-Gel acquires Gorlin syndrome drug candidate Patidegib from PellePharm Sol-Gel Technologies, an Israel-based dermatology company, has acquired patidegib, a Gorlin syndrome drug candidate in phase 3 development,… byRaghuram KadariJanuary 31, 2023